Last reviewed · How we verify

Anaerobic Endometritis — Treatment Landscape & Competitive Intelligence

Anaerobic Endometritis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anaerobic Endometritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cleocin T CLINDAMYCIN PHOSPHATE Pfizer Lincosamide Antibacterial 1972-01-01
Cleocin clindamycin Generic (originally Upjohn/Pfizer) Lincosamide antibiotic 50S ribosomal protein L10 1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Upjohn/Pfizer) · 1 drug in Anaerobic Endometritis
  2. Pfizer · 1 drug in Anaerobic Endometritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anaerobic Endometritis:

Cite this brief

Drug Landscape (2026). Anaerobic Endometritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anaerobic-endometritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing